Accuray Incorporated · NASDAQ:ARAY
Accuray — Q4 FY2023 Earnings Presentation
13 slides from Accuray's earnings presentation, Aug 9, 2023
Slide 1: Q4'FY23 Earnings Call August 9, 2023
Q4’FY23 Earnings Call August 9, 2023
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. 2 Proprietary and Confidential Property of Accuray Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are
Slide 3: Accuray FY23 Highlights
Accuray FY23 Highlights Global Leader in Precision Radiation Therapy Vision: To expand the curative power of radiation therapy to improve as many lives as possible Russell 2000® Index Broad-market Russell 3000® Index New Headquarters Location Madison, WI 9% $448M Growth in system volume over prior y
Slide 4: Executive Team
Executive Team Suzanne Winter President and CEO Ali Pervaiz Senior Vice President, Chief Financial Officer Sandeep Chalke Senior Vice President, Chief Commercial Officer Seth Blacksburg Senior Vice President, Chief Medical Officer Jesse Chew Senior Vice President, Chief Legal Officer Mike Hoge Senio
Slide 5: RT Strongly Positioned for Value-based Care
RT Strongly Positioned for Value-based Care U.S. Cancer Expenditures Estimate ($ Billion)1,2 1: Dieguez G., Ferro C., Pyenson B.S. A multi-year look at the cost burden of cancer care: Milliman research report. https://milliman-cdn.azureedge.net/-/media/Milliman/importedfiles/uploadedFiles/insight/20
Slide 6: VitalHold Breast Package for the Radixact System
VitalHold™ Breast Package for the Radixact® System Breast cancer treatments represent more than 20% of cases seen by radiation oncology departments1,2 510(k) clearance for full commercialization in the U.S.; available for ordering in the EU market3 Facilitates higher precision breast treatments Radi
Slide 7: Q4'FY23 and FY23 Financials
Q4’FY23 and FY23 Financials Strong financial performance FY23 Highlights Historic revenue milestone with 24% growth in system volume over prior year Revenue adjusted for FX exceeded the high-end of FY23 guidance by $10M 5% growth in global installed base year over year Underlying service revenue gro
Slide 8: FY24 Guidance
FY24 Guidance Takes into account expectations regarding uncertainty and impact from macro environmental climate, FX and inflation Revenue Adjusted EBITDA1 $447.6M $23.9M FY24 Guidance Range FY23 Actual $ in millions % = YoY Growth $460M - $470M +3% - 5% $27M - $30M +13% - 25% 1 Adjusted EBITDA is a
Slide 9: In Summary
In Summary Historic revenue milestone with 24% growth in system volume in FY23 Strongest product portfolio and pipeline in company’s history Multiple growth catalysts and global commercial execution Advancing margin expansion and free cash flow initiatives Positioned for Long-Term Revenue Growth and
Slide 10: Thank you
ACCURAY Thank you
Slide 11: GAAP to Adjusted EBITDA Q4 FY'23 and Q4 FY'22 Actual
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization Three Months Ended June 30, Three Months Ended June 30, 2022 2023 $ $ $ $ (2,556) 1,097 2,452 2,735 580 5,208 (3,452) 1,275 2,694 2,028 2,027 5,166 ERP an
Slide 12: GAAP to Adjusted EBITDA FY2023 and FY2022 Actual
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization Twelve Months Ended June 30, Twelve Months Ended June 30, 2022 2023 $ $ $ $ (9,280) 4,527 10,053 10,340 2,492 23,948 (5,347) 5,522 10,600 8,109 3,345 22,8
Slide 13: GAAP to Adjusted EBITDA FY'24 Forward Looking Guidance
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization To From $ $ $ $ (1,000) 4,500 10,500 10,000 2,000 27,000 2,000 4,500 10,500 10,000 2,000 30,000 ERP and ERP related expenditures 1,000 1,000 GAAP to Adjus